SynthesisBMC anesthesiology2026
Complications of controlled hypotension during functional endoscopic sinus surgery - a systematic review.
Synthesis in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough functional endoscopic sinus surgery (FESS) constitutes a standard treatment for the management of chronic rhinosinusitis, intraoperative bleeding poses a considerable challenge by impairing visibility and increasing complication risks. Controlled hypotension is a widely employed technique to mitigate bleeding; however, excessive blood pressure reduction may compromise systemic perfusion and predispose to organ ischemia.
objectivesDue to the scarcity of literature evaluating the safety of controlled hypotension in FESS, we aimed to systematically review current evidence on the risks and potential complications of this technique, with an emphasis on systemic adverse events (hemodynamic instability, neurological impairment, and renal dysfunction).
methodsThe PubMed, Embase, and Cochrane databases were searched for English-language original articles published until October 1, 2025. Studies were considered eligible if they reported mean arterial pressure (MAP) values achieved and evaluated systemic complications associated with controlled hypotension during FESS.
resultsA total of 32 articles were found eligible and included in the further analysis. Most protocols aimed for a MAP of 50-70 mmHg, primarily using dexmedetomidine, propofol, and remifentanil. Only 8 of the 32 studies utilized advanced intraoperative monitoring (e.g., near-infrared spectroscopy [NIRS], transcranial Doppler [TCD], and non-invasive cardiac output monitoring [NICOM]). The most frequent minor complication was postoperative nausea and vomiting (in 2-62% of cases). Significant hemodynamic disturbances included intraoperative bradycardia and severe hypotension (MAP < 50 mmHg), requiring pharmacological intervention. While no permanent neurological deficits were reported, intraoperative cerebral desaturation was observed in 2 studies. The follow-up observation rarely extended beyond the post-anesthesia care unit and did not include a structured assessment of cerebral and renal function.
conclusionsSubclinical complications of controlled hypotension during FESS may be overlooked without advanced intraoperative monitoring, postoperative biomarker surveillance, and a long-term follow-up period. The application of a uniform MAP target of 50-70 mmHg may be insufficient in high-risk patients. The development of personalized hemodynamic management strategies and enhanced perfusion-monitoring protocols is required to reduce the risk of occult organ ischemia and to define safe limits for controlled hypotension in FESS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.